Maravai LifeSciences Holdings Balance Sheet Health
Financial Health criteria checks 4/6
Maravai LifeSciences Holdings has a total shareholder equity of $777.4M and total debt of $523.3M, which brings its debt-to-equity ratio to 67.3%. Its total assets and total liabilities are $1.4B and $667.3M respectively.
Key information
67.3%
Debt to equity ratio
US$523.33m
Debt
| Interest coverage ratio | n/a |
| Cash | US$561.69m |
| Equity | US$777.39m |
| Total liabilities | US$667.25m |
| Total assets | US$1.44b |
Recent financial health updates
Recent updates
Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) 29% Jump Shows Its Popularity With Investors
Jul 18
Does Maravai LifeSciences Holdings (NASDAQ:MRVI) Have A Healthy Balance Sheet?
Jul 15Maravai: Embedded Expectations Remain Too High Considering Economic Calculus
Jul 12RGA Investment Advisors - Maravai: Two Elite Assets With Other-Worldly Margins Wrapped In One
Jun 12Revenues Tell The Story For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) As Its Stock Soars 25%
May 14An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued
Apr 07Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Feb 28Revenues Working Against Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price
Dec 19Need To Know: Analysts Just Made A Substantial Cut To Their Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Estimates
Aug 14Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 27%?
Feb 28Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 01Maravai Lifesciences temporarily reinstates Carl Hull as CEO
Oct 19Maravai LifeSciences appoints former Danaher executive as CEO
Oct 03Maravai LifeSciences Holdings GAAP EPS of $0.53 beats by $0.15, revenue of $242.73M beats by $9.51M
Aug 04Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
Jun 27Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 25% Below Its Share Price
Mar 29Maravai Faces Skeptical Investors As Pandemic Enters New Period
Jan 27Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price Could Signal Some Risk
Dec 02Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 26% Below Its Share Price
Oct 07Financial Position Analysis
Short Term Liabilities: MRVI's short term assets ($667.9M) exceed its short term liabilities ($59.0M).
Long Term Liabilities: MRVI's short term assets ($667.9M) exceed its long term liabilities ($608.2M).
Debt to Equity History and Analysis
Debt Level: MRVI has more cash than its total debt.
Reducing Debt: MRVI's debt to equity ratio has reduced from 229.6% to 67.3% over the past 5 years.
Debt Coverage: MRVI's debt is not well covered by operating cash flow (6.2%).
Interest Coverage: Insufficient data to determine if MRVI's interest payments on its debt are well covered by EBIT.